Statin may slow progressive MS

Discussion of statins (Lipitor, Zocor, etc.) in the treatment of MS.
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Statin may slow progressive MS

Post by MSUK » Wed Oct 10, 2012 11:45 am


High-dose simvastatin (Zocor) significantly reduced brain atrophy and slowed advancement of disability for 2 years in patients with secondary progressive multiple sclerosis, researchers said here.

In a 140-patient randomized trial, patients receiving 80 mg/day of simvastatin had an annualized rate of brain volume loss of just 0.298% compared with 0.589% among those given placebo (P=0.003), reported Jeremy Chataway, MA, PhD, of University College London in England.

Significant reductions in disability progression, as measured by EDSS and MS Impact Score (MSIS), were also seen with simvastatin in the trial, he told attendees at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis.... Read More - ... ageid/1319

User avatar
Family Elder
Posts: 3367
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Statin may slow progressive MS

Post by CureOrBust » Thu Sep 12, 2013 4:37 am

I am thinking this is another take on the same story. ... 3/statins/
Statins are oral medications that are most commonly prescribed to lower cholesterol. Current interest is based on a non-controlled observational study (a study without a placebo group) suggesting that the risk of developing new brain lesions was reduced by about half if patients with early forms of MS were taking atorvastatin (Lipitor®). However, a three-year Danish study of patients with RRMS failed to find any beneficial effect for simvastatin as an add-on therapy to Avonex. The use of statins to lower cholesterol in patients on interferons should be discussed with a healthcare professional to consider the potential benefits versus risks.

At the ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) annual meeting in Fall 2012, Chataway and colleagues presented the results of the MS-STAT trial.42 This Phase II study evaluated whether high-dose simvastatin can slow the rate of whole-brain atrophy, and/or disability, in secondary-progressive MS (SPMS). In this study, 140 patients were randomized, and the simvastatin group had a statistically significant benefit over the placebo group for the Expanded Disability Status Scale (EDSS) at two years, and the rate of brain atrophy was decreased. This serves as a positive proof-of-principle project that may allow for a larger trial that can look at the clinical outcomes as the primary outcomes measure. As effective treatments for SPMS remain an unmet need, and since these are readily available drugs, this is a tantalizing possibility.

Post Reply
  • Similar Topics
    Last post

Return to “Statins”